Combination of a leadless pacemaker and subcutaneous implantable cardioverter defibrillator therapy for a Japanese patient with prosthetic valve endocarditis

Ito, Ryo; Kondo, Yusuke; Winter, Joachim; Hayashi, Toshimitsu; Nakano, Miyo; Kajiyama, Takatsugu; Nakano, Masahiro; Kobayashi, Yoshio

doi:10.1002/joa3.12152

Cited by 8 publications

(7 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The combination therapy has been reported in older patients with vascular occlusion, post-infection. 2 , 3 , 4 Most previous reports described an order of the procedure in which the S-ICD was implanted first, followed by the leadless pacemaker. However, in the present case, we first performed leadless pacemaker implantation, after which the patient underwent an S-ICD screening test, and then we implanted the S-ICD.…”

Section: Discussionmentioning

confidence: 99%

Treatment Strategy for Fatal Arrhythmias in Ebstein’s Anomaly Combined With Leadless Pacemaker and S-ICD Implantations

Takami

Fukuzawa²,

Kiuchi³

et al. 2022

JACC: Case Reports

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Treatment Strategy for Fatal Arrhythmias in Ebstein’s Anomaly Combined With Leadless Pacemaker and S-ICD Implantations

Takami

Fukuzawa²,

Kiuchi³

et al. 2022

JACC: Case Reports

View full text Add to dashboard Cite

“…S-ICDs have the following two disadvantages: (I) antitachycardia pacing cannot be performed with an S-ICD, and (II) unlike ICDs with transvenous leads, S-ICDs do not have a pacemaker function for bradycardia except after shock. Ito et al reported a case in which an S-ICD was implanted in a patient with ventricular tachycardia who had a history of mechanical valve infective endocarditis and a leadless pacemaker was placed for subsequent bradycardia ( Figure 3 ) ( 14 ). In addition, attempts are being made to develop a novel modular cardiac rhythm management system consisting of a communicating antitachycardia pacing-enabled leadless pacemaker and an S-ICD ( 15 ).…”

Section: Device Therapy For Patients With Svc Obstructionmentioning

confidence: 99%

Superior vena cava obstruction and cardiovascular implantable electronic devices—a new era of leadless devices

Kabutoya

2024

Mediastinum

View full text Add to dashboard Cite

Cardiovascular implantable electronic devices (CIEDs) such as pacemakers and implantable cardioverter defibrillators require the placement of a transvenous lead through the superior vena cava (SVC), which can be difficult if there is stenosis or obstruction of the SVC. Moreover, SVC syndrome may occur after the lead is inserted even if the SVC was intact before the implantation. Therefore, there is need of an appropriate strategy for handling stenosis or obstruction of SVC during lead placement. In addition, advances are being made in CIEDs that do not require transvenous leads, and thus CIEDs without a transvenous lead should be considered depending on the indications and urgency of the particular case. This manuscript is divided into (I) device therapy for patients with SVC obstruction and (II) therapeutic strategy for SVC obstruction after lead implantation. In patients with SVC syndrome, treatment of the SVC occlusion should be based on the individual pathophysiology, and depending on the indications and urgency of the case, treatment with CIEDs that do not require transvenous leads should be considered. Further data must be accumulated to clarify the long-term prognosis of device implantation after treatment of SVC occlusion. In addition, transvenous lead extraction is now widely used for device-related SVC obstruction, and this procedure also merits further accumulation of data.

show abstract

“…Though not specifically involving the CHD population, 2019 saw the release of several additional studies examining the real-world combination of leadless pacemakers and S-ICDs for both the application of bradycardia pacing as well as the termination of ventricular tachycardia with antitachycardia pacing. Ito et al, 5 Ljunstrom et al, 6 and Baroni et al 7 all described the successful implantation and midterm follow-up outcomes of patients who received an S-ICD and the Micra™ leadless pacemaker (Medtronic, Minneapolis, MN, USA). The patient described by Ito et al had prosthetic valve endocarditis precluding transvenous pacing but tolerated leadless pacing with no evidence of S-ICD crosstalk and displayed appropriate eligibility in all sensing vectors (ie, primary, secondary, and alternative) during ventricular pacing.…”

Section: Subcutaneous Implantable Cardioverter Defibrillatorsmentioning

confidence: 99%

State of Cardiac Implantable Electronic Devices in Congenital Heart Disease: A 2019 Update

Alvensleben¹,

Collins²

2019

J Innov Cardiac Rhythm Manage.

View full text Add to dashboard Cite

The prevalence of adult congenital heart disease (CHD) is directly attributable to the success of pediatric cardiology and congenital cardiac surgery in diagnosing and managing cardiac conditions in childhood. The observed success with this population has resulted in the application of electrophysiological techniques and therapies to an expanding population of patients, bypassing previous limitations secondary to size, underlying knowledge base, or both. Cardiac implantable electronic devices (CIEDs) are no exception and the last decade has seen a remarkable expansion into the CHD population. The 2014 Pediatric and Congenital Electrophysiology Society (PACES) and the Heart Rhythm Society (HRS) expert consensus statement on the recognition and management of arrhythmias in adult CHD 1 and the 2018 American Heart Association/American College of Cardiology guidelines for the management of adults with CHD 2 underscore that the care of these patients continues to become formalized. The year 2019 saw the release of several studies examining the impact of CIEDs in CHD with a focus placed on subcutaneous implantable cardioverter defibrillators (S-ICDs), epicardial devices, cardiac resynchronization therapy (CRT) systems, and leadless pacing. Subcutaneous implantable cardioverter defibrillatorsThe release of the S-ICD was heralded as a result of its utility in patients with limited vascular access and contraindications to the implantation of transvenous systems. This, the lack of intravascular components, and the concomitant need for lead extraction made the S-ICD particularly favorable in the CHD population, where patients are typically younger and frequently present with atypical venous return. This year saw the release of several larger series describing the acute and midterm outcomes of S-ICD implantation and served to enhance our understanding of this device type in this challenging group of patients.At the 2019 HRS Scientific Sessions, a collaborative presentation organized together with the PACES described 116 pediatric and adult patients who had undergone S-ICD implantation, including 37 who had CHD. 3 Among the entire cohort, the investigators found that 97.9% of patients experienced a successful first-shock cardioversion during implant testing and 92.5% demonstrated the delivery of appropriate therapy during a follow-up period of 33 months ± 29 months. Complications were comparable to those reported in other studies of CIEDs in this population, with 18.9% of patients experiencing any of a variety of selected complications. Notably, infections requiring device removal were low (1.7%) and no cases of endocarditis were 3940

show abstract

Combination of a leadless pacemaker and subcutaneous implantable cardioverter defibrillator therapy for a Japanese patient with prosthetic valve endocarditis

Cited by 8 publications

References 5 publications

Treatment Strategy for Fatal Arrhythmias in Ebstein’s Anomaly Combined With Leadless Pacemaker and S-ICD Implantations

Treatment Strategy for Fatal Arrhythmias in Ebstein’s Anomaly Combined With Leadless Pacemaker and S-ICD Implantations

Superior vena cava obstruction and cardiovascular implantable electronic devices—a new era of leadless devices

State of Cardiac Implantable Electronic Devices in Congenital Heart Disease: A 2019 Update

Contact Info

Product

Resources

About